Fc-enhanced anti-CTLA-4 depletes tumor-infiltrating regulatory T cells to augment immune effects of androgen ablation in high-risk prostate cancer

R. Ager, Casey; Obradović, Aleksandar; McCann, Patrick; G. Chaimowitz, Matthew; L.E. Wang, Alexander; Shaikh, Neha; Shah, Parin; Pan, Samuel; Laplaca, Caroline; K. Virk, Renu; C. Hill, Jessica; Jugler, Collin; DeFranco, Grace; Bhattacharya, Nilika; R. Copple, Kade; I. Scher, Howard; Joel DeCastro, G.; B. Anderson, Christopher; M. McKiernan, James; S. Spina, Catherine; N. Stein, Mark; Runcie, Karie; G. Drake, Charles; Califano, Andrea; C. Dallos, Matthew

doi:10.1101/2024.09.09.24313308

Public

Fc-enhanced anti-CTLA-4 depletes tumor-infiltrating regulatory T cells to augment immune effects of androgen ablation in high-risk prostate cancer

Published in medRxiv • Sep 11, 2024

Authors:

Casey R. Ager

Aleksandar Obradović

Patrick McCann

Abstract

Abstract Despite high rates of post-surgical recurrence in men with high-risk localized prostate cancer (PCa), there is currently no role for neoadjuvant therapy. Tumor infiltrating regulatory T cells (TI-Tregs) limit the antitumor effects of presurgical androgen deprivation therapy (ADT). Therefore...

Subject

Prostate cancer

Medicine

Androgen deprivation therapy

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!